A little knowledge bomb for most of the NOOBS here
“I think the true value of cabo can be viewed in terms of it as a franchise, having franchise potential across multiple indications outside of the initial potential indication around thyroid cancer,” Morrissey said according to a transcript of the Nov. 15 conference. “Certainly the vast majority of our Phase 2 work over the last few years has been focused in other tumor indications.”
The treatment will carry a boxed warning alerting patients about the possibility of experiencing severe and fatal bleeding and holes in the colon, the FDA said today.
In addition to prostate cancer, Exelixis is testing cabozantinib in breast, ovarian and renal cancers, as well as solid tumors, non-small cell lung cancer and multiple myeloma. The treatment is the FDA’s 31st new drug approval this year, surpassing a seven-year high of 30 approvals in 2011.
Err... 150% to 300% for immedeate rise? LOL
I'll take a quadruple ANY time, my friend, but I don't have such hopes...
I think we will be in the 5.75 area and I would be happy with that.
I mean, EVERYONE pretty much knew that cabo will be approved by the FDA. Remember they skipped that review meeting a couple of months ago (because they had already decided). So I don't think anyone was surprised. I wasn't.
let me clarify... the bashers are trying to dampen a forest fire with a spoon of water by saying "ooh look the market is so small" The market is just a lovely size worldwide and Cabo has many many applications beyond thyroid cancer.